Real-world insights on cardiometabolic, glycemic, and safety outcomes of dapagliflozin-based therapy in patients with type 2 diabetes
Crossref DOI link: https://doi.org/10.30574/wjarr.2026.29.2.0228
Published Online: 2026-02-28
Update policy: https://doi.org/10.30574/wjarr.ourcrossmarkpolicy
T, Rakesh
Reddy P, Tejeshwar
L, Meenakshisundaram
Basavaraju, Basavaraju
Shankar, J Ravi
